TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Fujirebio Diagnostics AB
Closing information (x1000 DKK)
| Closing information | 2025/03 (consolidated) | 2024/03 (consolidated) | 2023/03 (consolidated) |
| Turnover |
215,417
|
207,841
|
205,365 |
| Financial expenses |
10,474
|
2,805
|
55 |
| Earnings before taxes |
94,930
|
108,564
|
117,202 |
| EBITDA |
109,456
|
112,135
|
121,469 |
| Total assets |
496,415
|
501,305
|
425,812 |
| Current assets |
296,090
|
308,168
|
221,630 |
| Current liabilities |
74,807
|
78,597
|
32,897 |
| Equity capital |
415,594
|
417,396
|
387,859 |
| - share capital |
441
|
415
|
423 |
| Employees (average) |
93
|
89
|
86 |
Financial ratios
| Fiscal year | 2025/03 (consolidated) | 2024/03 (consolidated) | 2023/03 (consolidated) |
| Solvency |
83.7%
|
83.3%
|
91.1% |
| Turnover per employee |
2,316
|
2,335
|
2,388 |
| Profit as a percentage of turnover |
44.1%
|
52.2%
|
57.1% |
| Return on assets (ROA) |
21.2%
|
22.2%
|
27.5% |
| Current ratio |
395.8%
|
392.1%
|
673.7% |
| Return on equity (ROE) |
22.8%
|
26.0%
|
30.2% |
| Change turnover |
-5,472
|
6,665
|
30,221 |
| Change turnover % |
-2%
|
3%
|
17% |
| Chg. No. of employees |
4
|
3
|
11 |
| Chg. No. of employees % |
4%
|
3%
|
15% |
Total value of public sale
| Fiscal year | 2025/03 (consolidated) | 2024/03 (consolidated) | 2023/03 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.